45 abstracts found.



Results filter

FOxTROT: an international randomised controlled trial in 1052 patients evaluating neoadjuvant chemotherapy for colon cancer

Year:

Session type:

Theme:

Dion Morton, on behalf of the FOxTROT investigators1
1University of Birmingham, Birmingham, UK

ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers

Year:

Session type:

Theme:

Angela Lamarca1,Daniel H Palmer2,Harpreet Singh Wasan3,Paul J Ross4,Yuk Ting Ma5,Arvind Arora6,Stephen Falk7,Roopinder Gillmore8,Jonathan Wadsley9,Kinnari Patel10,Alan Anthoney11,Anthony Maraveyas12,Tim Iveson13,Justin S Waters14,Claire Blesing10,Safia Barber15,David Ryder15,John Ramage16,Linda Davies17,John A. Bridgewater18,Juan W Valle19
1The Christie NHS Foundation Trust, Manchester, UK,2University of Liverpool, Liverpool, UK,3Department of Cancer Medicine, Hammersmith Hospital, London, UK,4Guy's and St Thomas' NHS Foundation Trust, London, UK,5University of Birmingham, Birmingham, UK,6University Hospital of Nottingham NHS Trust, Nottingham, UK, University of Nottingham, Nottingham, UK,7Bristol Haematology and Oncology Centre, Bristol, UK,8Royal Free Hospital, London, UK,9Weston Park Hospital, Sheffield, UK,10Oxford University Hospitals, Oxford, UK,11Leeds Teaching Hospitals NHS Trust, Leeds, UK,12Castle Hill Hospital, Hull, UK,13University Hospital Southampton NHS Foundation Trust, Southampton, UK,14Kent Oncology Centre, Maidstone, UK,15Clinical Trials Unit, University of Manchester, Manchester, UK,16Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK,17Health Economics Department, University of Manchester, Manchester, UK,18University College London Cancer Institute, London, UK,19Institute of Cancer Sciences, University of Manchester, Manchester, UK, The Christie NHS Foundation Trust, Manchester, UK

ACUFOCIN: Randomised clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (CIPN)

Year:

Session type:

Theme:

Jacqui Stringer1,Andrew Wardley1,David Ryder2
1The Christie NHS Trust,2University of Manchester

Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial.

Year:

Session type:

Theme:

Peter Hall1,Daniel Swinson2,Simon Lord3,Helen Marshall4,David Cairns4,Sharon Ruddock4,Emma Batman4,Galina Velikova4,Russell Petty5,Justin Waters6,Jonathan Wadsley7,Stephen Falk8,Catherine Handforth9,Rajarshi Roy10,Mano Joseph11,Konstantinos Kamposioras12,Jonathan Nicoll13,Tania Tillett14,Sebastian Cummins15,Simon Grumett16,Zuzana Stokes17,Tom Waddell18,Anirban Chatterjee19,Angel Garcia20,Christine Allmark21,Matthew Seymour22
1University of Edinburgh, Edinburgh, UK,2Leeds Teaching Hospitals NHS Trust, Leeds, UK,3University of Oxford, Oxford, UK,4University of Leeds, Leeds, UK,5University of Dundee, Dundee, UK,6Kent Oncology Centre, Maidstone, UK,7Western Park Hospital, Sheffield, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9University of Sheffield, Sheffield, UK,10Castle Hill Hospital, Hull, UK,11The Royal Wolverhampton NHS Trust, Wolverhampton, UK,12Mid Yorkshire Hospitals NHS Trust, Wakefield, UK,13North Cumbria University Hospitals NHS Trust, Carlisle, UK,14Royal United Hospital Bath NHS Trust, Bath, UK,15Royal Surrey County Hospital NHS Foundation Trust, Guilford, UK,16The Dudley Group NHS Foundation Trust, Dudley, UK,17United Lincolnshire Hospitals NHS Trust, Lincoln, UK,18The Christie NHS Foundation Trust, Manchester, UK,19The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK,20The Shrewsbury and Telford Hospital NHS Trust,21NCRI Consumer Forum, London, UK,22University of Leeds

BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab +/- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer Patients

Year:

Session type:

Theme:

Harpreet Wasan1,Tobias Arkenau2,Mike Braun3,Leslie Samuel4,Janet Graham5,Scott Kopetz6,Axel Grothey7,Eric Van Cutsem8,Rona Yaeger9,Takayuki Yoshino10,Jayesh Desai11,Fortunato Ciardello12,Ashwin Gollerkeri13,Kati Maharry13,Victor Sandor13,Janna Christy-Bittel13,Lisa Anderson13,Josep Tabernero14
1Hammersmith Hospital, London, UK,2Sarah Cannon Research Institute, London, UK,3Manchester Academic Health Science Centre and The Christie NHS Foundation Trust, Manchester, UK,4Aberdeen Royal Infirmary, Aberdeen, UK,5Beatson West Of Scotland Cancer Centre, Glasgow, UK,6UT MD Anderson Cancer Center, Houston, US,7West Cancer Center, University of Tennessee, Knoxville, US,8University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium,9Memorial Sloan-Kettering Cancer Center, New York, US,10National Cancer Center Hospital East, Kashiwa, Japan,11Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia,12University of Campania, Caserta, Italy,13Array BioPharma Inc, Boulder, US,14Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain

Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial

Year:

Session type:

Theme:

Robert Jones1,Margherita Carucci2,Angela Casbard2,Rachel Butler3,Catherine Bale4,Fouad Alchami5,Pavel Bezecny6,Johnathan Joffe7,Sarah Moon8,Chris Twelves9,Ramachandran Venkitaraman10,Simon Waters1,Sacha Howell11
1Velindre University NHS Trust, Cardiff, UK,2Cardiff University, Cardiff, UK,3North Bristol NHS Trust, Bristol, UK,4Betsi Cadwaladr University Health Board, Bangor, UK,5Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK,6Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK,7Royal College of Physicians of London, London, UK,8University Hospitals of Morecambe Bay NHS Trust, Milnthorpe Cumbria, UK,9University of Leeds and St. James's Institute of Oncology, Leeds, UK,10The Ipswich Hospital NHS Trust, Ipswich, UK,11The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

Scheduling nab-paclItaxEl combined with GEmcitabine as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in the SIEGE randomised trial: a test of bench to bedside concept.

Year:

Session type:

Theme:

Pippa Corrie1,Wendi Qian1,Aarthi Gopinathan2,Juan W. Valle3,Bristi Basu4,Stephen Falk5,Chinenye Iwuji6,Harpreet Wasan7,Daniel Palmer8,Martin Scott-Brown9,Jonathan Wadsley10,Seema Arif11,John Bridgewater12,David Propper13,Roopinder Gillmore14,Michael Williams2,Rebecca Brais1,Katy Dalchau1,Lisa Bax1,Purity Bundi1,Richard Skells1,Andrea Machin1,Albrecht Neesse15,David Tuveson16,Duncan Jodrell1
1Cambridge University Hospitals NHS Foundation Trust,2Cancer Research UK - Cambridge Institute,3The Christie Hospital NHS Foundation Trust,4Cambridge University Hospital NHS Foundation Trust,5Bristol Haematology and Oncology Centre,6Leicester Royal Infirmary,7Hammersmith Hospital - Imperial College Healthcare NHS Trust,8Clatterbridge Cancer Centre NHS Foundation Trust,9,10Weston Park Hospital - Sheffield,11Velindre Cancer Centre - Cardiff,12University College London Hospitals NHS Foundation Trust,13Barts Health NHS Trust,14The Royal Free Hospital - London,15Universitätsmedizin Göttingen - Vorstand,16Cold Spring Harbor Laboratory - NY

Final DFS results of the SCOT study: An international Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 months vs 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer

Year:

Session type:

Theme:

Timothy Iveson1,Rachel S Kerr2,Mark P Saunders3,Jim Cassidy4,Niels Henrik Hollander5,Josep Tabernero6,Andrew Haydon7,Bengt Glimelius8,Andrea Harkin4,Karen Allan4,John McQueen4,Claire Scudder9,Kathleen Anne Boyd10,Andrew Briggs10,David Propper11,John Bridgewater12,Ashraf Azzabi13,David Farrugia14,Andrew Webb15,David Cunningham16,Tamas Hickish17,Andrew Weaver18,Simon Gollins19,Harpreet S Wasan20,James Paul4
1University Hospital Southampton,2University of Oxford, Department of Oncology, Oxford,3The Christie Hospital, Manchester,4Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow,5Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5, DK 4700, Naestved,6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona,7Australasian Gastro-Intestinal Trials Group (AGITG),8University of Uppsala,9OCTO, University of Oxford, Department of Oncology, Oxford,10Institute of Health and Wellbeing, University of Glasgow, Glasgow,11Barts Cancer Institute, Queen Mary, University of London, London,12University College London, London,13Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle,14Gloucestershire Oncology Centre, Cheltenham General Hospital,15Brighton and Sussex University Hospital Trust, Brighton,16Royal Marsden, London UK (funded by NIHR BRC at the Royal Marsden),17Poole Hospital/Bournemouth University, Bournemouth,18Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford,19North Wales Cancer Treatment Centre, Rhyl,20Hammersmith Hospital, Imperial College London, London

Combined analysis of the FOXFIRE prospective randomised studies of first-line selective internal radiotherapy in patients with liver metastases from colorectal cancer

Year:

Session type:

Theme:

Ricky Sharma1,Peter Gibbs2,E. Anne Francis3,Sarah Pearson4,Sharon Love5,Joanna Moschandreas5,Peter Dutton5,Pradeep S. Virdee5,Val Lewington6,Greg Wilson7,Paul Tait8,Nas Khan9,Dave Berry10,Andy Wotherspoon11,Bruno Morgan12,Ian Chau13,Amir Montazeri14,Daniel Swinson15,Ewan Brown16,Sarah Lowndes17,Paul Ross18,Joanne Hornbuckle19,Alastair Gray20,Guy van Hazel21,Harpreet Wasan22,FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators FOXFIRE, SIRFLOX and FOXFIRE-Global trial investigators23
1University College London,2Western Hospital, Footscray, Victoria,3Oncology Clincal Trials Office, Department of Oncology, University of Oxford,4Oncology Clinical Trials Office, Department of Oncology, University of Oxford,5Centre for Statistics in Medicine, University of Oxford,6Nuclear Medicine Department, Guy's Hospital, King's College London,7The Christie NHS Foundation Trust,8Imperial College London,9Royal Marsden and Chelsea & Westminster Hospital,10University Hospital Southampton,11The Royal Marsden NHS Foundation Trust,12University of Leicester,13Royal Marsden Hospital, London and Surrey,14The Clatterbridge Cancer Centre NHS foundation Trust, Wirral,15Leeds Teaching Hospital NHS Trust,16Edinburgh Cancer Centre, Western General Hospital, Edinburgh,17Great Western Hospitals NHS Foundation Trust Great Western Hospital, Swindon,18Guy's & St Thomas' NHS Foundation Trust, London,19Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,20Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford,21University of Western Australia, Perth,22Imperial College Healthcare NHS Trust & Imperial College,23University of Oxford

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Year:

Session type:

Theme:

Philippa Corrie1,Andrea Marshall2,Paul Nathan3,Paul Lorigan4,Martin Gore5,Saad Tahir6,Guy Faust7,Charles Kelly8,Maria Marples9,Sarah Danson10,Ernest Marshall11,Stephen Houston12,Ruth Board13,Ashita Waterston14,Jenny Nobes15,Mark Harries16,Satish Kumar17,Gemma Young1,Emily Barker1,Janet Dunn18,Mark Middleton19
1Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge,2Warwick Clinical Trials Unit, University of Warwick, Coventry,3Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex,4University of Manchester and Christie NHS Foundation Trust, Manchester,5Royal Marsden Hospital NHS Trust, London,6Oncology Research, Broomfield Hospital, Chelmsford,7Oncology Department, Leicester Royal Infirmary, Leicester,8Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne,9St James’s Institute of Oncology, St James’s University Hospital, Leeds,10Academic Unit of Clinical Oncology, Sheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield,11Cancer & Palliative Care, St. Helen’s Hospital, St. Helens,12Oncology Department, Royal Surrey County Hospital, Surrey,13Rosemere Cancer Centre, Royal Preston Hospital, Preston,14Clinical Trials Unit, Beatson WOS Cancer Centre, Glasgow,15Dept of Clinical Oncology, Norfolk & Norwich University Hospital, Norwich,16Guy’s & St. Thomas’ Hospital, London,17Velindre Cancer Centre, Cardiff,18University of Warwick,19Oxford NIHR Biomedical Research Centre, Oxford

The NCRI Myeloma XI study: a large adaptive randomised clinical trial successfully answering a diverse range of key questions in multiple myeloma.

Year:

Session type:

Theme:

Walter Gregory1,Graham Jackson2,Charlotte Pawlyn3,David Cairns1,Alina Striha1,Anna Waterhouse1,John Jones3,Bhuvan Kishore4,Mamta Garg5,Cathy Williams6,Kamaraj Karunanithi7,Jindriska Lindsay8,Matthew Jenner9,Gordon Cook1,Martin Kaiser3,Mark Drayson10,Roger Owen11,Nigel Russell12,Faith Davies13,Gareth Morgan14
1University of Leeds,2University of Newcastle,3The Institute of Cancer Research, London,4Department of Haematology and Stem Cell Transplantation, Heart of England NHS Foundation Trust, Birmingham,5Leicester Royal Infirmary,6Nottingham University Hospital,7University Hospital of North Midlands, Stoke-on-Trent,8East Kent Hospitals University NHS Foundation Trust,9University Hospital Southampton NHS Foundation Trust,10University of Birmingham,11Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds,12Department of Haematology, Nottingham University Hospitals NHS Trust,13,14Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Adjuvant capecitabine for biliary tract cancer (BTC): The UK BILCAP randomized study

Year:

Session type:

Theme:

John Bridgewater1,Richard Fox2,Daniel Palmer3,Raj Prasad4,Darius Mirza5,Alan Anthoney6,Pippa Corrie7,Stephen Falk8,Harpreet Wasan9,Paul Ross10,Lucy Wall11,Jonathan Wadsley12,Jeff Evans13,Deborah Stocken2,Raaj Praseedom7,David Cunningham14,James Garden15,Clive Stubbs2,Juan Valle16,John Primrose17
1UCL,2Cancer Research UK Clinical Trials Unit, University of Birmingham,3University of Liverpool,4University of Leeds,5QE Hospital & Birmingham Children's Hospital,6Leeds Teaching Hospitals NHS Trust,7Addenbrooke's Hospital NHS Trust,8University Hospitals Bristol,9Imperial Healthcare NHS Trust,10Guys and St Thomas’ NHS Trust,11Lothian NHS Trust,12jonathan.wadsley@sth.nhs.uk,13Beatson Institute,14Royal Marsden NHS Trust,15University of Edinburgh,16The Christie,17University of Southampton

Perioperative chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: mature analysis of overall survival in the New EPOC randomised controlled trial

Year:

Session type:

Theme:

John Bridgewater1,Siân Pugh2,Amy Whitehead3,Louise Stanton3,Zina Eminton3,Jane Mellor3,Alex Allen3,Meg Finch-Jones4,Stephen Falk4,Tim Iveson5,Myrddin Rees6,Juan Valle7,Jo Hornbuckle8,Tamas Hickish9,David Cunningham10,Tim Maughan11,O James Garden12,Gareth Griffiths3,John Primrose2,New EPOC Investigators3
1University College London,2University of Southampton,3Southampton Clinical Trials Unit,4University Hospitals Bristol NHS Foundation Trust,5University Hospital Southampton NHS Foundation Trust,6Hampshire Hospitals NHS Foundation Trust,7The Christie NHS Foundation Trust,8Sheffield Teaching Hospitals NHS Foundation Trust,9Poole Hospital and Bournemouth University,10The Royal Marsden Hospital NHS Foundation Trust,11CRUK/MRC Oxford Institute for Radiation Oncology,12The University of Edinburgh

Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM)

Year:

Session type:

Theme:

Anthony Chalmers1,Garth Cruickshank2,Laurence Dunn3,Sara Erridge4,Lisa Godfrey5,Christopher Herbert6,Sarah Jefferies7,Juanita Lopez8,Catherine McBain9,Marc Pittman5,Rebecca Sleigh10,Colin Watts11,Mark Webster-Smith5,Sarah Halford5
1Glasgow Centre for Cancer Research,2University of Birmingham,3University of Glasgow,4University of Edinburgh,5Cancer Research UK,6University Hospitals Bristol NHS Foundation Trust,7Cambridge University Hospitals NHS Trust,8Institute of Cancer Research,9The Christie NHS Foundation Trust,10LGC,11University of Cambridge

Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE(NCT00268476)

Year:

Session type:

Theme:

Nicholas D James1,13,Matthew R Sydes2,Malcolm D Mason3,Noel W Clarke14,David P Dearnaley4,Melissa R Spears2,Robin Millman15,Christopher C Parker8,Alastair W S Ritchie2,J Martin Russell5,John Staffurth11,Robert J Jones5,Shaun P Tolan6,John Wagstaff7,Andrew Protheroe8,Rajaguru Srinivasan9,Alison J Birtle10,Joe M O’Sullivan11,Richard Cathomas12,Mahesh K B Parmar2

1University of Warwick, Coventry, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Velindre Hospital, Cardiff, UK,4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK,5Beatson West of Scotland Cancer Centre, Glasgow, UK,6Clatterbridge Cancer Centre, Wirral, UK,7South West Wales Cancer Institute, Swansea, UK,8University of Oxford Medical Oncology Department, Oxford, UK,9Royal Devon and Exeter NHS Foundation Trust, Exeter, UK,10Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,11Belfast City Hospital, Belfast, UK,12Kantonsspital Chur, Chur, Switzerland,13Queen Elizabeth Hospital, Birmingham, UK,14The Christie and Salford Royal Hospitals, Manchester, UK,15Prostate Cancer Support Group, Middlesbrough, UK


CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy treatment-naïve patients (pts) with advanced melanoma (MEL)

Year:

Session type:

Theme:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean Grob5,Charles Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Arvin Yang16,Linda Rollin17,Christine Horak16,James Larkin18,Stephen Hodi19

1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,2Oncology Institute of Veneto IRCCS, Padua, Italy,3University of Colorado Cancer Center, Denver, CO, USA,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland,5Hospital de la Timone, Marseille, France,6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA,7University of Michigan, Ann Arbor, MI, USA,8Department of Dermatology, University of Essen, Essen, Germany,9European Institute of Oncology, Milan, Italy,10Cross Cancer Institute, Edmonton, AB, Canada,11Universitäts Spital, Zurich, Switzerland,12Tasman Oncology Research, Queensland, Australia,13Netherlands Cancer Institute, Amsterdam, The Netherlands,14Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy,15Peter MacCallum Cancer Centre, Victoria, Australia,16Bristol-Myers Squibb, Princeton, NJ, USA,17Bristol-Myers Squibb, Wallingford, CT, USA,18Royal Marsden Hospital, London, UK,19Dana-Farber Cancer Institute, Boston, MA, USA


PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT)

Year:

Session type:

Theme:

Hisham Mehanna1,Wai Lup Wong2,Christopher A McConkey3,Joy K Rahman3,Max Robinson4,Andrew Hartley5,Christopher Nutting6,Ned Powell7,Hoda Al-Booz8,Martin Robinson9,Elizabeth Junor10,Claire Hulme11,Alison F Smith11,Peter Hall12,Bal Sanghera2,Janet A Dunn3

1InHANSE, University of Birmingham, Birmingham, UK,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Warwick University Clinical Trials Unit, Coventry, UK,4Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle, UK,5Queen Elizabeth Hospital Birmingham, Birmingham, UK,6Royal Marsden Hospital, London, UK,7HPV Oncology Group, Institute of Cancer Genetics, Cardiff University, Cardiff, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Weston Park Hospital, Sheffield, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11University of Leeds, Leeds, UK,12St James University Hospital, Leeds, UK


A phase II/III randomised trial comparing maintenance lapatinib vs placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer

Year:

Session type:

Theme:

Simon Chowdhury2,Tony Elliot3,Robert Jones4,Syed Hussain5,Simon Crabb6,Charlotte Ackerman1,Satinder Jagdev7,John Chester7,Serena Hilman8,Mark Beresford8,Graham Macdonald9,Sundar Santhanam10,John Frew11,Andrew Stockdale12,Shah-Jalal Sarker1,Dan Berney1,Thomas Powles1,Robert Huddart13

1Barts Cancer Institute, London, UK,2Guy’s and St Thomas’ Hospital NHS Trust, London, UK,3The Christie NHS Foundation Trust, Manchester, UK,4Beatson West of Scotland Cancer Centre, Glasgow, UK,5The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,6University Hospital Southampton NHS Foundation Trust, Southampton, UK,7St James’s University Hospital, Leeds, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Aberdeen Royal Infirmary, Aberdeen, UK,10Nottingham University Hospitals NHS Trust, Nottingham, UK,11Freeman Hospital, Newcastle, UK,12University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK,13Royal Marsden Hospital, Surrey, UK


Development of novel imaging methods in mouse cancer models

Year:

Session type:

Kevin Brindle1

1University of Cambridge, Cambridge, UK


Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA)

Year:

Session type:

Christopher Parker1, Daniel Heinrich2, Joe M. O'Sullivan3, Sophie Foss
1The Royal Marsden Hospital, Surrey, UK, 2Haukeland University Hospital, Bergen, Norway, 3Centre for Cancer Research and Cell Biology, Queen

Comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma: A Phase III randomised, open-label, multicentre trial (BRIM3)

Year:

Session type:

James Larkin1, Paul B. Chapman2, Grant A. McArthur3, Paul Lorigan4, Paul Nathan5, Mark R. Middleton6, Axel Hauschild7
1Royal Marsden Hosptial, London, UK, 2Memorial Sloan-Kettering Cancer Center, New York, USA, 3Peter MacCallum Cancer Centre, Melbourne, Australia, 4University of Manchester, Manchester, UK, 5Mount Vernon Hospital, London, UK, 6University of Oxford Cancer Centre, Oxford, UK, 7University of Kiel, Kiel, Germany

Optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) for women with early breast cancer (EBC): results of the SECRAB trial. Presented on behalf of the SECRAB Steering Committee

Year:

Session type:

Indrajit Fernando1, Sarah Bowden2,1, Deborah Stocken2, Robert Grieve3, David Spooner1, Rajiv Agrawal4, Murray Brunt5, Mark Churn6, Andrea Stevens1, Andrea Marshall7, Daniel Rea2,1, Peter Canney8
1University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, 2University of Birmingham, Birmingham, UK, 3University Hospital, Coventry, UK, 4Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK, 5University Hospital North Staffordshire, Stoke on Trent, UK, 6New Cross Hospital, Wolverhampton, UK, 7University of Warwick, Warwick, UK, 8Beatson West of Scotland Cancer Centre, Glasgow, UK

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute (NCRI) CLL206 Trial

Year:

Session type:

Andrew R Pettitt1,2, Richard Jackson1, Stacey Carruthers1, James Dodd1, Susanna Dodd1, Gillian G Johnson1, Anna Schuh3, Estella Matutes4, Claire Dearden4, Daniel Catovsky4, John Radford5,6, Adrian Bloor5,6, George A Follows7, Stephen Devereux8, Anton Kruger9, Julie Blundell9, Samir Agrawal10, David Allsup11, Stephen Proctor12, Earnest Heartin13
1University of Liverpool, Liverpool, UK, 2Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK, 3Oxford Radcliffe Hospitals NHS Trust, Oxford, UK, 4Institute of Cancer Research and Royal Marsden Hospital NHS Trust, Surrey, UK, 5The University of Manchester, Manchester, UK, 6Christie NHS Foundation Trust, Manchester, UK, 7Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 8King's College Hospital NHS Foundation Trust, London, UK, 9Royal Cornwall Hospitals NHS Trust, Cornwall, UK, 10Barts and The London NHS Trust, London, UK, 11Hull and East Yorkshire Hospitals NHS Trust, Hull, UK, 12University of Newcastle, Newcastle, UK, 13Conwy & Denbighshire NHS Trust, North Wales, UK, 14Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK, 15Leeds Teaching Hospitals NHS Trust, Leeds, UK

Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110)

Year:

Session type:

Malcolm Mason1, Matthew Sydes2, Wendy Parulekar3, Mahesh Parmar2, John Anderson4, Jim Barber5, Michael Brundage3, Richard Cowan6, Mary Gospodarowicz7, Charles Hayter8, John Hetherington9, Andrea Hiltz3, Peter Kirkbride10, Edward Kostashuk11, Karen Sanders2, Jinka Sathya12, Gregory Swanson13, Bingshu Chen3, Padraig Warde7
1Cardiff University, Cardiff, UK, 2MRC Clinical Trials Unit, London, UK, 3NCIC Clinical Trials Group, Kingston, Ontario, Canada, 4The Royal Hallamshire Hospital, Sheffield, UK, 5Velindre Hospital, Cardiff, UK, 6The Christie NHS Foundation Trust, Manchester, UK, 7Princess Margaret Hospital and University of Toronto, Toronto, Canada, 8Credit Valley Hospital, Mississauga, Canada, 9Castle Hill Hospital, Hull, UK, 10Weston Park Hospital, Sheffield, UK, 11British Columbia Cancer Agency, Surrey, British Columbia, Canada, 12CancerCare Manitoba, Winnipeg, Canada, 13University of Texas Health Science Centre at San Antonio, San Antonio, Texas, USA

The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial

Year:

Session type:

David Sebag-Montefiore1, Roger James2, Helen Meadows3, Rubina Begum3, David Cunningham4, John Northover5, Jonathan Lederman6,3, Sandra Beare3, Latha Kadalayil3, Robert Glynne-Jones7
1University of Leeds St James's Institute of Oncology, Leeds, UK, 2Maidstone Hospital, Maidstone, UK, 3CRUK and UCL Cancer Trials Centre, London, UK, 4Royal Marsden Hospital, London, UK, 5St. Marks Hospital, Harrow, UK, 6UCL Cancer Institute and UCL Hospitals, London, UK, 7Mount Vernon Centre for Cancer Treatment, Middlesex, UK

Treatment of advanced neuroendocrine tumours: final results of the UKI NETS and NCRI randomised phase 2 NET 01 trial

Year:

Session type:

Pippa Corrie1, Martyn Caplin2, Nick Reed3, Wendi Qian4, Si-houy Lao-Sirieix4, Richard Hardy4, Graham Armstrong4, Juan Valle5, Denis Talbot6, David Cunningham7, Tu Vinh Luong2, Ashley Shaw8, Tim Meyer2
1Oncology Centre, Addenbrooke's Hospital, Cambridge, UK, 2The Royal Free Hospital, London, UK, 3Beatson Oncology Centre, Glasgow, UK, 4Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, UK, 5Christie Hospital, Manchester, UK, 6Churchill Hospital, Oxford, UK, 7The Royal Marsden, London, UK, 8Radiology Department, Addenbrooke's Hospital, Cambridge, UK

Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib)

Year:

Session type:

David R Ferry10, Susan J Dutton1, Wasat Mansoor3, Joyce Thompson4, Mark Harrison5, Haider Abbas10, Asa Dahle-Smith2, Anirban Chatterjee6, Stephen Falk7, Angel Garcia-Alonso9, David Walter Fyfe8, Richard Hubner3, Tina Gamble4, Lynnda Peachey1, Mina Davoudianfar1, Sarah R Pearson1, Patrick Julier1, Janusz Jankowski11, Rachel Midgely1, Russell Petty2
1University of Oxford, Oxford, UK, 2University of Aberdeen, Aberdeen, UK, 3Christie Hospital NHS Foundation Trust, Manchester, UK, 4Birmingham Heartlands Hospital, Birmingham, UK, 5Mount Vernon Cancer Centre, Northwood, London, UK, 6Royal Shrewsbury Hospital, Shrewsbury, UK, 7Bristol Haematology and Oncology Centre, Bristol, UK, 8University Hospitals of Morecombe Bay, Lancaster, UK, 9North Wales Cancer Centre, Glan Clwyd, UK, 10Russells Hall Hospital, Dudley, UK, 11QMUL, London, UK

A randomised clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in KRAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study

Year:

Session type:

John Primrose1, Stephen Falk2, Meg Finch-Jones3, Juan Valle4, Joanne Hornbuckle5, Mark Peterson5, Ajith Siriwardena6, David Cunningham7, Graeme Poston8, Tim Maughan9, Myrrdyn Rees10, Derek O'Reilly11, Elizabeth Dixon12, Louisa Little12, Wendy Wood12, Megan Bowers12, Louise Stanton12, Tom Maishman12, Siân Pugh1, John Bridgewater13
1University Hospital Southampton, Southampton, UK, 2Bristol Haematology and Oncology Centre, Bristol, UK, 3University Hospitals Bristol, Bristol, UK, 4The Christie NHS Foundation Trust, Manchester, UK, 5Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, 6Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK, 7The Royal Marsden Hospital NHS Foundation Trust, London, UK, 8Aintree University Hospital NHS Foundation Trust, Liverpool, UK, 9Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK, 10Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK, 11The Pennine Acute Hospitals NHS Trust, Manchester, UK, 12University of Southampton Clinical Trials Unit, Southampton, UK, 13University College London Hospitals NHS Foundation Trust, London, UK

A multicenter phase III randomised double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC)

Year:

Session type:

Michael Seckl1, Christian Ottensmeier2, Mike Cullen3, Peter Schmid4, Lindsay James5, Christina Wadsworth5, Hannah Farrant5, Dakshinamoorthy Muthukumar6, Joyce Thompson7, Susan Harden8, Gary Middleton9, Kate Fife10, Barbara Crosse11, Paul Taylor12, Iftekhar Khan5
1Imperial College London, London, UK, 2Southampton University, Southampton, UK, 3Queen Elizabeth Hospital Birmingham, Birmingham, UK, 4Brighton and Sussex Medical School, Brighton, UK, 5Cancer Research UK and University College London CTC, London, UK, 6Colchester University Hospital NHS Foundation Trust, Colchester, UK, 7Heart of England NHS Trust, Birmingham, UK, 8Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 9Royal Surrey County Hospital, Guildford, UK, 10Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK, 11Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK, 12University Hospital South Manchester, Manchester, UK

Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma (HL) and a negative PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial

Year:

Session type:

John Radford1, Sally Barrington2, Nicholas Counsell3, Ruth Pettengell13, Peter Johnson4, Jennie Wimperis5, Stewart Coltart6, Dominic Culligan7, Andrew Lister8, Eric Bessell9, Anton Kruger10, Bilyana Popova3, Barry Hancock11, Peter Hoskin12, Tim Illidge1, Mike O'Doherty2
1The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, 2PET Imaging Centre, St Thomas' Hospital, London, UK, 3Cancer Research UK and UCL Cancer Trials Centre, London, UK, 4University of Southampton, Southampton, UK, 5Norfolk and Norwich University NHS Foundation Trust, Norwich, UK, 6Kent and Canterbury Hospital, Canterbury, UK, 7Aberdeen Royal Infirmary, Aberdeen, UK, 8Barts and the London School of Medicine, London, UK, 9Nottingham City Hospital, Nottingham, UK, 10Royal Cornwall Hospital, Truro, UK, 11University of Sheffield, Sheffield, UK, 12Mount Vernon Cancer Centre, Northwood, UK, 13St George's, University of London, London, UK

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

Year:

Session type:

JA Ledermann1, T Perren2, FA Raja1,3, AC Embleton3, GJS Rustin4, G Jayson5, SB Kaye6, A Swart7,3, M Vaughan8, H Hirte9
1Cancer Research UK & UCL Cancer Trials Centre, London, UK, 2St. James University Hospital, Leeds, UK, 3Medical Research Council Clinical Trials Unit at UCL, London, UK, 4Mount Vernon Hospital, Northwood, UK, 5Christie Hospital, Manchester, UK, 6Royal Marsden Hospitals, London, UK, 7University of East Anglia, Norwich, UK, 8Christchuch Hospital, Christchurch, New Zealand, 9Hamilton Regional Cancer Centre, Ontario, Canada

Introduction: Integration between oncology and palliative care

Year:

Session type:

Irene Higginson1

1King’s College London, London, UK


Prospective, multi-centre, case-control study to evaluate a novel Cytosponge™–TFF3 test for diagnosing Barrett’s oesophagus

Year:

Session type:

Caryn Ross-Innes1, Irene Debiram-Beecham1, Maria O’Donovan2, Elaine Walker1, Sibu Varghese1, Pierre Lao-Sirieix1, Laurence Lovat3, Michael Griffin4, Krish Ragunath5, Rehan Haidry3, Sarmed Sami5, Philip Kaye5, Marco Novelli3, Babett Disep4, Richard Ostler6, Benoit Aigret6, Bernard North6, Peter Sasieni6, Rebecca Fitzgerald1, BEST2 Study Group7

1MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge, UK,2Department Histopathology, Addenbrooke’s Hospital, Cambridge, UK,3University College London Hospital, London, UK,4Royal Victoria Infirmary, Newcastle upon Tyne, UK,5Nottingham Queen’s Medical Centre, Nottingham, UK,6Cancer Prevention Trials Unit, London, UK,7Multi-centre BEST2 Study group, England, UK


ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR)

Year:

Session type:

Helena Earl1,2, Louise Hiller3, Janet Dunn3, Clare Blenkinsop3, Louise Grybowicz4, Anne-Laure Vallier4, Jean Abraham1,5, Jeremy Thomas6, Elena Provenzano2,5, Luke Hughes-Davies5, Karen McAdam7, Stephen Chan8, Rizvana Ahmad9, Tamas Hickish10, Stephen Houston11, Daniel Rea12, John Bartlett13,14, Carlos Caldas1,15, David Cameron14, Larry Hayward6

1Department of Oncology, University of Cambridge, Cambridge, UK,2NIHR Cambridge Biomedical Research Centre, Cambridge, UK,3Warwick Clinical Trials Unit, University of Warwick, Coventry, UK,4Cambridge Clinical Trials Unit − Cancer Theme, Cambridge, UK,5Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,6Western General Hospital, Edinburgh, UK,7Peterborough City Hospital, Peterborough, UK,8Nottingham University Hospital City Campus, Nottingham, UK,9West Middlesex University Hospital, Isleworth, UK,10Royal Bournemouth Hospital, Bournemouth University, Bournemouth, UK,11Royal Surrey County Hospital, Guildford, UK,12Sandwell&West Birmingham NHS Trust; University Hospital Birmingham NHS Trust, Birmingham, UK,13Ontario Institute for Cancer Research, Ontario, Canada,14Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, UK,15Cancer Research UK Cambridge Research Institute, Cambridge, UK


REST- A Dutch/UK randomized phase III trial on the use of thoracic radiotherapy in extensive stage small-cell lung cancer

Year:

Session type:

Corinne Faivre-Finn1, Matthew Hatton2, Michael Snee3, Pooja Jain4, Paula Wilson5, Rhona McMenemin6, Clive Peedell7, Andrew Bates8, Angel Garcia9, Janet Ironside10, Sally Falk1, Harm van Tinteren11, Astrid Keijser12, Ben Slotman13

1The Christie NHS Foundation Trust, Manchester, UK,2Weston Park Hospital, Sheffield, UK,3St James’s University Hospital, Leeds, UK,4Clatterbridge Centre for Oncology, Wirral, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne, UK,7James Cook University Hospital, Middlesbrough, UK,8Southampton General Hospital, Southampton, UK,9North Wales Cancer Centre, Glan Clwyd Hospital, Rhyl, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11Netherlands Cancer Institute, Amsterdam, The Netherlands,12IKNL Clinical Research Department, Amsterdam, The Netherlands,13VU University Medical Center, Amsterdam, The Netherlands


ET: A randomised, multicentre, phase III trial to evaluate ERCC1 as a predictive biomarker for comparing platinum with nonplatinum chemotherapy, in patients with advanced/metastatic non-small cell lung cancer (NSCLC)

Year:

Session type:

Siow-Ming Lee1,15, Fiona Blackhall2, Abhro Chaudhuri3, Gary Middleton4, Samreen Ahmed5, Jonathan Hicks6, Barbara Crosse7, James Spicer8, Mark Napier9, Julian Singer10, Marianne Nicolson11, David Ferry12, Conrad Lewanski13, Sally Ann Rolls14, Mary Falzon1, Yenting Ngai15, Rachel Lillywhite15, Natasha Iles15, Robin Rudd15, Allan Hackshaw15

1University College London Hospital, London, UK,2Christie Hospital Manchester, Manchester, UK,3Lincoln County Hospital, Lincoln, UK,4Royal Surrey County Hospital, Guildford, UK,5Leicester Royal Infirmary, Leicester, UK,6New Victoria Hospital, Kingston upon Thames, UK,7Calderdale & Huddersfield NHS Foundation Trust, Huddersfield, UK,8Guys Hospital London, London, UK,9North Devon District Hospital, Barnstaple, UK,10Princess Alexandra Hospital, Harlow, UK,11Aberdeen Royal Infirmary, Aberdeen, UK,12New Cross Hospital Birmingham, Birmingham, UK,13Charing Cross Hospital, London, UK,14Withybush General Hospital, Haverfordwest, UK,15University College London, London, UK


Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

Year:

Session type:

Andrew Tutt

Breakthrough Breast Cancer Research Unit, Kings College London School of Medicine, Guy's Hospital, London, UK


MRC OV05/EORTC 55955 Ovarian Cancer Trial of early treatment of relapse based on CA125 level alone versus delayed treatment

Year:

Session type:

Gordon Rustin

Mount Vernon Cancer Centre, Northwood, UK


Results from the MRC COIN trial of first-line therapy for advanced colorectal cancer (aCRC)

Year:

Session type:

Tim Maughan

Cardiff University, UK


Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)

Year:

Session type:

Chris Nutting

Royal Marsden Hospital, London, UK


Results of ICON7: a phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Medical Research Council Cancer Trials Unit, presented on behalf of the GCIG ICON7 collaborators

Year:

Session type:

Jonathan Ledermann2, Charlie Gourley3, Sharadah Essapen4, Gordon Rustin5, Fiona Collinson1, Sheryl Sim1, Faisal Al-Terkait1, Clare Griffin6
2UCL Cancer Institute and Cancer Research UK and UCL Cancer Trials Centre, London, UK,3University of Edinburgh Cancer Research Centre and Western General Hospital, UK,4Royal Surrey County Hospital, Guildford, UK,5Mount Vernon Hospital, Northwood, UK,6Medical Research Council Cancer Trials Unit, London, UK

Results of BC2001: A 2×2 phase III randomised trial of synchronous chemo-radiotherapy (CRT) compared to radiotherapy (RT) alone and standard (sRT) versus reduced high-dose volume RT (rvRT) in muscle invasive bladder cancer (MIBC) (CRUK/01/004

Year:

Session type:

Syed Hussain1, Emma Hall2, Peter Jenkins3, Jean Tremlett4, Christine Rawlings5, Malcolm Crundwell6, Rebecca Lewis2, Carey Hendron1, Rachel Waters2, Robert Huddart2
2The Institute of Cancer Research, Sutton, UK,3Cheltenham General Hospital, UK,4Brighton and Sussex University Hospitals NHS Trust, UK,5South Devon Healthcare NHS Foundation Trust, Torbay, UK,6Royal Devon and Exeter Hospital, UK

The MRC Myeloma IX Trial: beneficial effects of thalidomide and zoledronic acid for newly diagnosed myeloma patients of all ages

Year:

Session type:

Walter Gregory1, Faith Davies2, Kim Cocks1, Sue Bell1, Alex Szubert1, Nuria NavarroCoy1, Mark Drayson3, Roger Owen4, Gordon Coo4, Fiona Ross5, Graham Jackson6, Sylvia Feyler7, John Ashcroft8, Gareth Morgan2
2The Institute of Cancer Research, Royal Marsden Hospital, London, UK,3University of Birmingham, UK,4St James’s University Hospital, Leeds, UK,5University of Southampton, UK,6University of Newcastle, UK,7Calderdale and Huddersfield NHS Trust, Huddersfield, UK,8Mid Yorkshire Hospitals NHS Trust, Wakefield, UK

Intergroup randomized controlled phase III trial of Androgen Deprivation Therapy (ADT) +/- Radiation Therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633)

Year:

Session type:

Padraig R Warde2, Matthew R Sydes3, Keyue Ding8, Mary K Gospodarowicz2, Gregory P Swanson4, Peter Kirkbride5, Ed Kostashuk6, John Hetherington7, Andrea Hiltz8, Karen Sanders3, John Anderson5, Jim Barber1, Mahesh KB Parmar3, Wendy Parulekar8
2Princess Margaret Hospital and University of Toronto, Canada,3MRC Clinical Trials Unit, London, UK,4University of Texas Health Science Center, San Antonio, USA,5Weston Park Hospital, Sheffield, UK,6British Columbia Cancer Agency, Surrey, Canada,7Castle Hill Hospital, Hull, UK,8NCIC Clinical Trials Group, Kingston, Canada

Combination of finasteride with the chemopreventive agent resveratrol, decreases proliferative capacity of prostate cancer cells at physiologically achievable doses

Year:

Session type:

Lynne Howells, Emma Blake, Karen Brown

University of Leicester, Leicester, UK